DE69430232D1 - Hemmung der Symptome des prämenstruellen Synchroms/dysphorische Erkrankungen der späten lutealen Phase - Google Patents

Hemmung der Symptome des prämenstruellen Synchroms/dysphorische Erkrankungen der späten lutealen Phase

Info

Publication number
DE69430232D1
DE69430232D1 DE69430232T DE69430232T DE69430232D1 DE 69430232 D1 DE69430232 D1 DE 69430232D1 DE 69430232 T DE69430232 T DE 69430232T DE 69430232 T DE69430232 T DE 69430232T DE 69430232 D1 DE69430232 D1 DE 69430232D1
Authority
DE
Germany
Prior art keywords
symptoms
premenstrual
synchrome
dysphoric
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69430232T
Other languages
English (en)
Other versions
DE69430232T2 (de
Inventor
Steven Anthony Fontana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of DE69430232D1 publication Critical patent/DE69430232D1/de
Application granted granted Critical
Publication of DE69430232T2 publication Critical patent/DE69430232T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69430232T 1993-12-21 1994-12-19 Hemmung der Symptome des prämenstruellen Synchroms/dysphorische Erkrankungen der späten lutealen Phase Expired - Fee Related DE69430232T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/171,148 US5389670A (en) 1993-12-21 1993-12-21 Methods of inhibiting the symptoms of premenstrual syndrome/late luteal phase dysphoric disorder

Publications (2)

Publication Number Publication Date
DE69430232D1 true DE69430232D1 (de) 2002-05-02
DE69430232T2 DE69430232T2 (de) 2002-11-14

Family

ID=22622728

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69430232T Expired - Fee Related DE69430232T2 (de) 1993-12-21 1994-12-19 Hemmung der Symptome des prämenstruellen Synchroms/dysphorische Erkrankungen der späten lutealen Phase

Country Status (18)

Country Link
US (2) US5389670A (de)
EP (1) EP0659412B1 (de)
JP (1) JPH07196503A (de)
KR (1) KR950016737A (de)
CN (1) CN1108255A (de)
AT (1) ATE214927T1 (de)
AU (1) AU8155994A (de)
CA (1) CA2138505A1 (de)
CZ (1) CZ321894A3 (de)
DE (1) DE69430232T2 (de)
DK (1) DK0659412T3 (de)
ES (1) ES2170767T3 (de)
HU (1) HUT71338A (de)
IL (1) IL112054A0 (de)
NO (1) NO944921L (de)
PT (1) PT659412E (de)
RU (1) RU94044488A (de)
ZA (1) ZA9410077B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) * 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6395494B1 (en) * 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
DE69435137D1 (de) 1993-05-13 2008-10-16 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US6417198B1 (en) 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
US20030083733A1 (en) * 1997-10-10 2003-05-01 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5514704A (en) * 1995-03-13 1996-05-07 Eli Lilly And Company Benzothiophenes to inhibit leukotrienes
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
CA2223595C (en) 1995-06-07 2008-08-05 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US5733937A (en) * 1996-02-28 1998-03-31 Pfizer Inc. Methods for alleviating symptoms of premenstrual syndrome and late luteal phase dysphoric disorder
IL120262A (en) * 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US5985932A (en) * 1996-02-28 1999-11-16 Pfizer Inc Inhibition of autoimmune diseases
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
US6110942A (en) * 1996-06-17 2000-08-29 Eli Lilly And Company Method for minimizing the uterotrophic effect of droloxifene
ZA982877B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
US6117911A (en) * 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6008232A (en) * 1997-08-20 1999-12-28 Eli Lilly And Company Methods for preventing headaches
US6096781A (en) * 1997-11-14 2000-08-01 Eli Lilly And Company 2-arylbenzo[B]thiophenes useful for the treatment of estrogen deprivation syndrome
US6288108B1 (en) 1998-06-16 2001-09-11 Eli Lilly And Company Methods for increasing levels of acetylcholine
WO1999065489A1 (en) 1998-06-16 1999-12-23 Eli Lilly And Company Methods for increasing levels of acetylcholine
US6258826B1 (en) 1998-10-13 2001-07-10 Eli Lilly And Company Pharmaceutical formulations and applications thereof for the treatment of estrogen deprivation syndrome
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
JP2008527169A (ja) * 2005-01-10 2008-07-24 イシウム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ イエルサレム 金属ナノ粒子の水系分散物
MX2022002400A (es) * 2019-08-26 2022-06-08 Period Pill Bv Tratamiento de los sintomas inducidos por el ciclo menstrual.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体

Also Published As

Publication number Publication date
CA2138505A1 (en) 1995-06-22
EP0659412B1 (de) 2002-03-27
ATE214927T1 (de) 2002-04-15
HUT71338A (en) 1995-11-28
EP0659412A3 (de) 1995-09-06
ES2170767T3 (es) 2002-08-16
IL112054A0 (en) 1995-03-15
JPH07196503A (ja) 1995-08-01
AU8155994A (en) 1995-06-29
US5389670A (en) 1995-02-14
EP0659412A2 (de) 1995-06-28
KR950016737A (ko) 1995-07-20
ZA9410077B (en) 1996-06-19
NO944921L (no) 1995-06-22
DK0659412T3 (da) 2002-06-17
CZ321894A3 (en) 1995-09-13
NO944921D0 (no) 1994-12-19
US5550150A (en) 1996-08-27
CN1108255A (zh) 1995-09-13
HU9403671D0 (en) 1995-02-28
DE69430232T2 (de) 2002-11-14
RU94044488A (ru) 1996-10-20
PT659412E (pt) 2002-08-30

Similar Documents

Publication Publication Date Title
DE69430232T2 (de) Hemmung der Symptome des prämenstruellen Synchroms/dysphorische Erkrankungen der späten lutealen Phase
NO20002440D0 (no) Hydroksam- og karboksylsyrederivater med MMP- og TNF- inhiberende aktivitet
ATE153240T1 (de) Behandlung peri-menopausaler syndrome
RU94045846A (ru) Применение производных бензотиофена для ингибирования тромбина
DE69427800D1 (de) Methode zur Hemmung der Endometriose
NO944919L (no) Fremgangsmåte for å inhibere atrofi av huden eller vagina
DK599789A (da) 3,5-di-tertiaer-butyl-4-hydroxyphenyl-1,3,4-thiadazoler og -oxadiazoler samt 3,5-di-tertiaer-butyl-4-hydroxyphenyl-1,2,4-thiadazoler, -oxadiazoler og -triazoler som anti-inflammatoriske midler
DE69430465D1 (de) Hemmung uteriner Fibrose
ATE168887T1 (de) Hemmung von dysfunctionalen uterusblutungen
DE69428877D1 (de) Hemmung einer Fehlentwicklung der Ovarien, verspüteter Pubertät oder sexuellem Infantilismus
ATE92960T1 (de) Alpha-1-antitrypsin-varianten, besonders verwendbar als kallikrein-inhibitoren.
ATE46332T1 (de) Spiro-imidazolidine als aldose-reduktaseinhibitoren.
DK0871626T3 (da) Triazoloner som apolipoprotein-B syntheseinhibitorer
UA26459C2 (uk) Іhгібітор впливу амілоїдhих білків
NO924806L (no) Etanoladdukter av 6-sulfonylsubstituerte 3-hydroksykromaner og deres anvendelse som inhalasjonsmiddel ved sykdommer
ES2037825T3 (es) Uso farmaceutico de tioeteres aromaticos.
FR2226163A2 (en) 2-Amino-5-methyl-4-phenyl-1-pyrrolines - with antidepressant and antiarrhythmic activity
TH23898B (th) วิธีการหยุดยั้งการออกฤทธิ์ของ il-6
NO942350L (no) Peptidforbindelse med terapeutisk aktivitet

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee